Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab plus chemotherapy|DRUG: Trastuzumab in combination with pyrotinib plus chemotherapy
Sponsor: Fudan University